Table 4.
Quality of life in groups.
| NHP | Group 1 (n = 32) | Group 2 (n = 32) | P (MWU) |
| NHP-PBaseline3rd week12th week | pA63.59 ± 28.7838.93 ± 34.76 † <0.001*47.28 ± 35.01‡ | pA71.12 ± 32.2953.21 ± 36.63† <0.001*62.59 ± 32.88‡ | 0.320.110.07 |
| NHP-ER | |||
| Baseline | 30.59 ± 27.89 | 41.71 ± 35.50 | 0.16 |
| 3rd week | 21.50 ± 23.85† 0.01 | 34.37 ± 35.48 0.007* | 0.09 |
| 12th week | 25.56 ± 25.42 | 38.50 ± 36.03 | 0.10 |
| NHP-S | |||
| Baseline | 33.71 ± 32.62 | 46.90 ± 34.94 | 0.12 |
| 3rd week | 17.78 ± 26.90† 0.001* | 39.12 ± 32.59 0.05 | 0.006* |
| 12th week | 22.71 ± 28.27‡ | 45.53 ± 32.69 | 0.004* |
| Change (0–12) | 11.00 ± 23.09 | 1.37 ± 12.66 | 0.04* |
| NHP-SI | |||
| Baseline | 18.93 ± 24.18 | 33.96 ± 38.95 | 0.06 |
| 3rd week | 10.31 ± 18.09 0.08 | 25.84 ± 35.78† 0.007* | 0.03* |
| 12th week | 17.18 ± 25.83 | 35.15 ± 39.18 | 0.03* |
| NHP-PA | |||
| Baseline | 27.78 ± 19.87 | 40.84 ± 30.33 | 0.05 |
| 3rd week | 17.37 ±17.56† 0.001* | 36.96 ± 32.15 0.25 | 0.04* |
| 12th week | 22.06 ± 19.25‡ | 40.09 ± 28.49 | 0.004* |
| NHP-EL | |||
| Baseline | 58.12 ± 34.58 | 72.34 ± 32.51 | 0.09 |
| 3rd week | 39.03 ± 32.87† 0.001* | 66.43 ±36.95 0.37 | 0.003* |
| 12th week | 49.90 ± 36.74‡ | 69.90 ±32.33 | 0.02* |
| NHP-T | |||
| Baseline | 233.5 ± 120.6 | 306.9 ± 164.1 | 0.04* |
| 3rd week | 144.1 ± 116.1† <0.001* | 253.1 ± 172.3† 0.001* | 0.004* |
| 12th week | 183.8 ± 128.3‡ | 292.1 ± 162.6 | 0.004* |
MWU: Mann–Whitney U test, A: ANOVA, †: baseline - 3rd week, ‡: baseline - 12th week differences within groups (Wilcoxon signed ranks test/paired samples test), * P < 0.05. P: Pain, ER: emotional reaction, S: sleep, SI: social isolation, PA: physical activity, EL: energy level, T: total.